Truist Securities Reiterates Buy on Vertex Pharmaceuticals, Maintains $456 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $456.
October 04, 2023 | 2:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Vertex Pharmaceuticals and maintained a price target of $456.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Vertex Pharmaceuticals. The maintained price target of $456 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100